Core Insights - Silo Pharma, Inc. has filed a patent application for its neurology drug SPC-14, aimed at treating Alzheimer's disease, which is exclusively licensed from Columbia University [1][3] Patent Details - The patent titled "Compositions and Methods for the Treatment of Alzheimer's Disease and Other Neurogenerative Disease" focuses on SPC-14's mechanism of action, targeting glutamate receptor NDMAR and serotonin 5-HT4 to alleviate cognitive and neuropsychiatric symptoms in Alzheimer's disease [2][4] Drug Development - Early pre-clinical studies indicate that SPC-14 has the potential to improve cognitive memory function [3] - The drug has shown efficacy in preclinical studies against luteinizing hormone (LH) stress, reducing learned helplessness, perseverative behavior, and hyponeophagia, which is a measure of anxiety [4] Company Overview - Silo Pharma is a developmental stage biopharmaceutical company that focuses on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system diseases [5] - The company's portfolio includes other innovative programs such as SPC-15 for PTSD and SP-26 for fibromyalgia and chronic pain, alongside preclinical assets targeting Alzheimer's disease and multiple sclerosis [5]
Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer's Drug